For the year ending 2025-12-31, CDIOW had -$2,716,857 decrease in cash & cash equivalents over the period. -$5,914,150 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -6,498,167 |
| Depreciation | 160,063 |
| Amortization | 238,065 |
| Stock-based compensation expense | 110,235 |
| Accounts receivable | -10,486 |
| Prepaid expenses and other current assets | -479,974 |
| Accounts payable and accrued expenses | 9,781 |
| Lease liability | -237,270 |
| Net cash used in operating activities | -5,726,833 |
| Purchases of property and equipment | 187,317 |
| Patent costs incurred | 231,993 |
| Net cash used in investing activities | -419,310 |
| Proceeds from sale of common stock and warrants, net of issuance costs | 3,803,498 |
| Payments of finance agreement | 374,212 |
| Net cash provided by financing activities | 3,429,286 |
| Net (decrease) increase in cash | -2,716,857 |
| Cash - beginning of year | 7,827,487 |
| Cash - end of year | 5,110,630 |
Cardio Diagnostics Holdings, Inc. (CDIOW)
Cardio Diagnostics Holdings, Inc. (CDIOW)